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Parenteral Nutrition (PN) is a valuable life saving intervention which can improve the nutritional status of hospitalized
malnourished patients. PN is associated with complications including the development of hyperglycemia. This paper aims to
provide a descriptive systematic review regarding the eﬀects of PN-induced hyperglycemia in hospitalized patients, either in the
intensive care unit or ward, while formulating and complementing existing guidelines on the administration of PN and glucose
monitoring in hospitalized patients. Medline and Pubmed were searched for relevant articles describing complications arising
from the development of hyperglycemia in patients receiving PN; four relevant studies were identiﬁed in the search. These articles
had diﬀerent glycemic targets and patient populations, and their protocols varied with regards to glycemic control. However, there
was consistency regarding the association between hyperglycemia and mortality in patients receiving PN. These studies highlight
the need for guidelines regarding monitoring and initiation of therapy in hyperglycemic patients. Unfortunately, all the currently
available studiesareretrospective in design;alarge, prospective, randomized controlled trial regarding glycemic control in patients
receiving PN is required for the development of standardized protocols.
1.Introduction
Parenteral nutrition (PN) is a form of intravenous nutri-
tional support, originally developed at the University of
Pennsylvania School of Medicine in 1968 to support mal-
nourished surgical patients [1]. Shortly thereafter, PN was
shown to be valuable in providing life-saving nutrition
for both complex medical and surgical patients with a
nonfunctioning GI tract. It has been well established that PN
has a beneﬁcial eﬀect in improving the nutritional status of
hospitalized malnourished patients [2] and is predominately
used in those patients who are unable to receive nutrition
either orally or enterally largely due to intestinal failure.
Despite the life saving beneﬁts attributed to PN, it is
known to be associated with a number of short- and long-
term complications including liver disease, catheter-related
sepsis, septic shock, ﬂuid and electrolyte abnormalities, and
hyperglycemia. Arguably, the interest in blood glucose con-
trol and subsequent consequences of hyperglycemia among
hospitalized patients receiving PN is rapidly increasing,
mirroring the interest in the general inpatient population.
The mechanism of harm from hyperglycemia on various
organ systems has not been well deﬁned but it is known that
hyperglycemia alters the activity of phagocytes, interfering
with neutrophil and monocyte functions [3]. Hyperglycemia
also increases inﬂammatory cytokines, oxidative stress and
promotes apoptosis [4–7]. Cell and tissue injury caused
by hyperglycemia through oxidative stress adversely aﬀects
the immune, cardiovascular and nervous system as well as
hemostasis, inﬂammation, and endothelial cell function [8].
Recent groups have described an increase in medical
complications and mortality occurring in both critically
ill and noncritically ill hyperglycemic inpatients receiving
PN [9–12]. The prevalence of hyperglycemia occurring in2 Gastroenterology Research and Practice
patients receiving PN is quite variable and ranges between
10–88% [9, 13, 14]. It has been well established that in-
hospital hyperglycemia occurring in patients without any
attributable risk factor is associated with higher mortality
rates. [15–17]. Three recent studies of hospitalized patients
including both critically ill and noncritically ill, identiﬁed
PN-associated hyperglycemia as a risk factor for devel-
opment of infection, cardiac, and renal dysfunction and
increased mortality [9–11]. A fourth study of hospitalized,
noncritically ill patients receiving PN found hyperglycemia
to be a risk factor for increased mortality alone [12]. There-
fore, the purpose of this manuscript is to provide a descrip-
tive systematic review examining the medical complications
of parenteral nutrition-associated hyperglycemia, and its
association with mortality in critically ill and noncritically ill
patients. It will also review glucose monitoring and therapy
regimens and its eﬀect in hospitalized inpatients.
2. Methods
A systematic review was carried out by two reviewers to
search for articles relevant to this topic using Medline and
PubMed applying the following search terms alone and
in combination: hyperglycemia, total parental nutrition,
and hospitalized patients. There were no language or time
frame limits. Inclusion criteria were articles that examined
hospitalized patients, critically or noncritically ill, receiving
parenteral nutrition and the eﬀects of hyperglycemia on
this population compared with those who did not develop
hyperglycemia. Articles were excluded if they did not
speciﬁcally look at this population. However, clinical studies,
reviews, consensus statements, and meta-analysis relevant to
the identiﬁcation and management of hospitalized hyper-
glycemic patients receiving PN were selected and included.
Articles found were assessed for eligibility and compared
between the two reviewers. The references and citations
were also reviewed to identify other relevant articles. Data
extracted included patient demographics, mean glucose
level, study deﬁnition of hyperglycemia, method of glucose
monitoring, duration of PN, outcomes/complications asso-
ciated with the development of hyperglycemia while receiv-
ing PN (i.e., mortality, acute renal failure, any complication,
any infection, etc.) as well as their odds ratios and 95%
conﬁdence intervals. Authors were contacted via email if the
papers lacked data that pertained to this study. The studies
were heterogeneous in their methods, therefore the data
could not be combined statistically, but general trends were
assessed.
3. Results
Thesearchresultedin38possiblearticles,whichwerefurther
narrowed down to four articles that met our eligibility
criteria. There was a kappa agreement of 100% between
the two reviewers on the inclusion of these articles. These
four retrospective studies [9–12] explored the relation-
ship between hyperglycemia and health outcomes and are
described in Table 1. Demographics were underreported in
these studies and hence they could not be combined for this
review.
Cheung et al. [9] were the ﬁrst group to look at adverse
outcomes associated with PN-induced hyperglycemia. They
conductedaretrospectiveanalysisreviewing109hospitalized
patients in the ward or the intensive care unit, who received
PN during the year 2002 in the Westmead Hospital, Sydney,
Australia. Mean blood glucose levels were calculated from
daily serum glucose readings taken for the duration that
patients were receiving PN. Hyperglycemic patients, deﬁned
as having blood glucose greater than 10mmol/L, would
undergo blood glucose testing q4 hours by ﬁnger prick and
PN calories would be reduced. If the blood glucose level
remained greater than 10mmol/L, the protocol called for
commencement of an insulin infusion for the duration of
PN therapy irrespective of whether the patient was critically
ill or not. Outcome measures included development of
any infection (culture proven), septicemia (blood culture
proven), cardiac complication (myocardial infarction, car-
diac arrhythmia, and cardiac arrest), acute renal failure, or
death (during admission). The mean duration of PN was
12.1 ± 20.4 days and the mean daily blood glucose during
PN was 8.0 ± 1.5mmol/L.
Lin et al [10] conducted a similar study in a group of
patients, also with mixed indications, in the Taipei Veterans
General Hospital, Taipei, Taiwan during the year 2004. A ret-
rospective cohort study including 457 hospitalized patients
was undertaken to determine associations between hyper-
glycemia and adverse outcomes in patients receiving PN.
All euglycemic subjects had serum glucose measurements
twice a week. In this study, patients were deﬁned as having
hyperglycemia if a single blood glucose measurement was
greater than 6.3mmol/L. Hyperglycemic patients underwent
capillary glucose testing q6 hours by ﬁnger prick. The
number of blood glucose values per patient ranged from 1 to
207; the mean blood glucose level was calculated using these
capillary glucose readings. Treatment of hyperglycemia was
not outlined in the methods. Outcome measures included
parameters described by Cheung et al. [9]. Additionally,
documented bacteremia, fungemia, and respiratory failure
deﬁned as the requirements for mechanical ventilation while
receiving PN were included as additional clinical outcomes.
The mean duration of PN was 17.8±17.7 days and the mean
daily blood glucose was 8.6 ± 3.2mmol/L.
Pasquel et al. [11] conducted a retrospective study of
276 hospitalized patients, in the ward and the intensive
care unit at the Grady Memorial Hospital, Atlanta, Georgia,
United States during the year 2006. Blood glucose levels
on admission, pre-PN, within 24 hours of initiation of PN,
and during days 2–10 of PN were included in the analysis.
Hyperglycemia was deﬁned as a blood glucose level above
6.7mmol/L. The monitoring and treatment of these patients
was not outlined in the methodology. Outcome measures
included mortality, development of any infections, length of
stay (LOS), and renal failure. The mean duration of PN was
15±24days.Themeandailybloodglucoseonadmissionwas
7.7±4.7mmol/L. The mean blood glucose prior to initiation
of PN was 6.8 ± 1.8mmol/L and increased to a mean blood
glucose of 8.1 ± 2.4mmol/L within 24 hours and remainedGastroenterology Research and Practice 3
Table 1: Characteristics of the studies examining hyperglycemia in patients receiving PN.
Study Cheung (2005) Lin (2007) Sarkisian (2009) Pasquel (2009)
Study Design Retrospective Retrospective Retrospective Retrospective
#of Patients 109 457 100 276
Patient Population Mixed Mixed Mixed Noncritically Ill only
Mean Age ± SD 51.9 ±18.76 6 .4 ±16.36 1 .9 ±17 51 ±18
Glucose Monitoring
Daily and capillary
glucose testing q4
hours for duration of
PN
Twice weekly and
capillary glucose
testing q6 hours for
duration of PN
Variable, including
ﬁrst 9 days on PN
On admission, pre PN
and daily for PN day
1–10
Mean Glucose Blood Draw Finger Prick Blood Draw & Finger
Prick Blood Draw
Blood glucose cut
points examined
(mmol/L)
<6.9 <6.3 <10 <6.7
6.9−7.8 6.3−7.6 ≥10.0 6.7−8.3
7.9−9.1 7.6−10 8.4−10
>9.1 >10.0 >10.0
elevated at 7.8 ± 2.2mmol/L for the remainder of the days
analyzed.
Sarkisian et al. [12] conducted a retrospective study of
100 hospitalized patients in the Foothills Medical Centre,
Calgary, Canada. This cohort excluded critically ill individu-
als unlike the preceding three studies outlined [9–11]. Mean
b l o o dg l u c o s ev a l u e sw e r ec a l c u l a t e df o re a c hp a t i e n tb a s e d
on the total number of readings during their ﬁrst 9 days
receiving PN including serum and ﬁnger prick readings.
Hyperglycemia was deﬁned as mean blood glucose levels
above 10mmol/L. Outcomes measured included develop-
ment of any infection, acute coronary event, acute renal
failure, LOS, ventilator use, ICU admission, and death.
Additionally, this group reviewed the median frequency of
glucose monitoring in both euglycemic and hyperglycemic
patients and the association of the frequency of monitoring
with mortality.
3.1.Mortality. Allfourstudiesshowedsigniﬁcantlyincreased
mortality in patients with mean blood sugars greater than
10mmol/LwhilereceivingPNafteradjustingforage,gender,
and previous diabetes status, when compared to a lower
blood glucose group (Table 2). Pasquel et al. [11] were the
only group to examine blood glucose levels at diﬀering
time periods in relation to PN initiation. They grouped the
patientsintothreegroups;pre-PNinitiation,within24hours
of PN initiation, and during days 2–10 of PN. In comparison
to living patients, deceased patients in their cohort had a
signiﬁcantly higher blood glucose pre-PN (7.2 ±2.1mmol/L
versus 6.7 ± 1.8mmol/L), within 24 hours of PN initiation
(9.0 ±3.1mmol/L versus 7.7 ±2.1mmol/L) and during days
2-10 of PN (8.9 ± 2.9mmol/L versus 7.9 ± 1.9mmol/L).
Their study indicates that blood glucose values prior to and
within 24 hours of initiation of PN are better predictors of
hospital mortality and complications than the mean blood
glucoseduringtheentiredurationofPN.Pasqueletal.found
that mortality was independently predicted by pre-PN blood
glucosevaluesbetween8.4-10mmol/L(OR3.41,95%CI1.3–
8.7, P<. 01) and greater than 10mmol/L (OR 2.2, 95% CI
0.9–5.2, P = .077), as well as by blood glucose within 24
hours of PN greater than 10mmol/L (OR 2.8 95% CI 1.2–
6.8, P = .020) versus patients without hyperglycemia.
3.2. Complications. Not all the groups agreed on the asso-
ciation between hyperglycemia and complications (Table 2).
Sarkisian et al. [12] did not ﬁnd an association between
hyperglycemia and acute coronary events, renal failure,
infection, hospital length of stay, ventilator use, or admission
to a critical care unit. This may be in part due to the
less critically ill population studied in comparison to the
other three studies which included both critically ill and
noncritically ill patients. Cheung et al. [9] found that for
every 1mmol/L increase in blood glucose above 6.9mmol/L,
the risk of any complication increased by a factor of 1.58.
Patients with a mean blood glucose greater than 9.1mmol/L
had the highest relative risk for complications (OR of 4.3,
95% CI 1.4–13.1 P = .01) using blood glucose of less than
6.9mmol/L as the reference. Lin et al. [10] found a similar
association. For every 0.56mmol/L increase in blood glucose
above 6.3mmol/L the risk of any complication increased by
a factor of 1.14. The highest relative risk of complications
was in the group of patients with mean blood glucose greater
than 10mmol/L (OR of 5.5, 95% CI 2.5–12.4 P<. 001)
using blood glucose of less than 6.3mmol/L as the reference
category. Pasquel et al. [11] noted that patients with higher
blood glucose levels during TPN had a longer hospital (P =
.011) and ICU length of stay (P = .008). They also found an
association between the risk of pneumonia (OR=3.6, 95% CI
1.6–8.4) and acute renal failure (OR=2.2, 95% CI 1.0–4.8) in
patients with blood glucose greater than 10mmol/L during
the ﬁrst 24 hours of TPN compared with patients having a
mean blood glucose less than 6.7mmol/L.
3.3. Monitoring. Blood glucose monitoring methods and
frequency was reported in each of the studies’ methods,
but not all examined the eﬀect on outcomes. Unfortu-
nately, it was not reported if monitoring was considerably
diﬀerent between the critically ill and noncritically ill4 Gastroenterology Research and Practice
Table 2: Risk of mortality and complications due to hyperglycemia in patients receiving PN.
Study Cheung (2005) Lin (2007) Sarkisian (2009) Pasquel (2009)
Hyperglycemia(mmol/L) >9.1∗ >10∗∗ >10∗∗∗ >10∗∗∗∗
Mortality OR(95%CI) 10.90(2.0 − 60.5)
X 5.0(2.4 −10.6)
X 7.22(1.08 −48.3)
X 2.80(1.20 −6.80)
X
Any Infection OR(95%CI) 3.9(1.2 −12.0)
X 3.1(1.5 −6.5)
X 0.9(0.3−2.5) NA
Cardiac OR(95%CI) 6.2(0.7−57.8) 1.6(0.3-7.2) 1.3(0.1−12.5) NA
Acute Renal Failure OR(95%CI) 10.9(1.2 −98.1)
X 3.0(1.2 −7.7)
X 1.9(0.4−8.6) 2.2(1.0−4.8)
Septicemia OR(95%CI) 2.5(0.7−9.3) NA NA NA
Any Complication OR(95%CI) 4.3(1.4 −13.1)
X 5.5(2.5 −12.4)
X NA NA
All study results are adjusted for age and sex.
X Signiﬁcant at P<. 05.
∗ORs are expressed using blood glucose <6.9mmol/L as a reference category.
∗∗ORs are expressed using blood glucose <6.3mmol/L as a reference category.
∗∗∗ORs are expressed using blood glucose <10mmol/L as a reference category.
∗∗∗∗ORs are expressed using blood glucose <6.7mmol/L as a reference category as measured within 24 hours of PN initiation.
patients included in these studies. Of these four studies,
only Sarkisian et al. [12] examined the frequency of blood
glucose monitoring and outcomes related to this. Patients
with hyperglycemia had their blood glucose monitored more
frequently in both the ﬁrst 48 hours (median 4 times, IQR:
2–7, P = .003) and in the ﬁrst week (median 6 times,
IQR: 3–18, P ≤ .001) compared to euglycemic patients.
There was no association between frequency of glucose
monitoring and mortality in the ﬁrst 48 hours of PN or
in the subsequent week of PN. The other studies reported
varying schedules to monitor hyperglycemia and did not
statistically analyze complications or mortality associated
with monitoring frequency.
4. Discussion
In our descriptive systematic review of the four available
retrospective studies examining hyperglycemia in hospi-
talized patients receiving PN, one consistent ﬁnding was
observed; mortality was increased signiﬁcantly if blood sug-
ars were above 10mmol/L. Unfortunately, of the published
studies examining hyperglycemia in PN patients, glycemic
targets diﬀered, patient populations were not identical,
protocols for monitoring blood sugars varied, and there
was a lack of information regarding hyperglycemic and
euglycemic control. These heterogeneous methods likely
account for the variations in results regarding complications
and morbidity associated with hyperglycemia. Three of
these studies included both critically ill and noncritically ill
patients and assessed outcomes in a homogeneous manner,
not accounting for potential confounding factors in their
analysis such as the indication for PN. This limitation in
study design demonstrates the need for the establishment
of large, controlled trials regarding glycemic control in
more homogenous patients receiving PN, either critically
ill or noncritically ill, for the development of standardized
protocols regarding monitoring and glucose therapy in PN
patients.
All four studies failed to monitor blood glucose to the
level suggested by The American Society of Parenteral and
Enteral Nutrition (A.S.P.E.N) [18]. To our knowledge, this
expert organization in nutrition support practices has the
onlypublishedsetofestablishedguidelinesregardingglucose
monitoring in patients receiving PN. They suggest glucose
monitoring q6 hours upon initiation of PN and at least
three times daily within days 3–9 until the blood glucose
has reached less than 11mmol/L. These guidelines do not
give further recommendations regarding closer monitoring
for critically ill patients. Based on the ﬁndings from Cheung,
Lin, Pasquel, and Sarkisian [9–12], the level of 11mmol/L
recommended by A.S.P.E.N as an indicator of acceptable
blood sugars may need to be further reduced.
Several studies with heterogeneous designs and outcome
measures have examined the relationship between tight
glycemic control and outcomes in critically ill patients.
Griesdale and colleagues report results from a meta-analysis
of 26 studies involving over 13,500 patients [19]. The
original landmark study conducted by Van den Berge et
al. [20] compared intensive insulin therapy versus con-
ventional treatment among surgical intensive care patients,
predominantly PN fed. Fasting blood glucose targets were
4.4–6.1mmol/L and 10-11.1mmol/L in the intensive and
conventional arms, respectively. They demonstrated a 34%
decrease in mortality with intensive insulin therapy. How-
ever,subsequentstudiesinslightlydiﬀerentpopulationshave
failed to show such beneﬁt. The Normoglycemia in Intensive
Care Evaluation-Survival Using Glucose Algorithm Regu-
lation (NICE-SUGAR) is currently the largest randomized
controlled study comparing intensive versus conventional
glucose control among both surgical and medical inten-
sive care patients who were predominantly enterally fed.
The NICE-SUGAR study deﬁned intensive glucose control
with a target blood glucose range of 4.5–6.0mmol/L and
conventional control as a target of 10.0mmol/L or less.
The authors found that intensive glucose control increased
the absolute risk of death at 90 days by 2.6% compared
with conventional glucose control. This represents a number
needed to harm of 38. There was also a 6-fold increase in
the rate of occurrence of hypoglycemia with use of intensive
therapy in all ICU patients [21]. Since the publication of
these studies and the recent meta-analysis, the American
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Association (ADA) have generated a consensus statement
which adopts less stringent blood glucose targets between
7.8–10.0mmol/L for critically ill patients to prevent hypo-
glycemia, while controlling for hyperglycemia [22, 23]. They
also recommend intravenous insulin infusions for critically
ill patients and subcutaneous basal-bolus, prandial and
correctional dosing for all noncritically ill patients [24, 25].
Based on the aggregated results from the 4 studies examining
outcomes in PN patients and the guidelines from the ACE
and the ADA described above, we could conclude that
the mean blood glucose in patients receiving PN, whether
they are critically ill or noncritically ill, should be less
than 10mmol/L and potentially the appropriate target range
would lie between 6.3 to 9.1mmol/L.
Only Cheung et al. clearly outlined treatment of hyper-
glycemia in their patients. Their protocol called for an
insulin infusion for all patients irrespective of their inpa-
tient location if during PN treatment blood sugars were
persistently above 10mmol/L. Treatment of hyperglycemia
with insulin infusion was associated with an increased rate
of complications (OR 2.7, 95% CI 1.3–5.6, P = 0.01),
although not statistically signiﬁcant for death. There were
no documented cases of hypoglycemia in patients receiving
insulin infusions. Incidentally, the mean blood glucose levels
for these patients were signiﬁcantly higher than patients
who did not require insulin therapy, suggesting that insulin
infusions were inadequately administered. This was the only
study in our review to examine treatment of hyperglycemia,
and the evidence is inconclusive regarding harm or beneﬁt
of the use of insulin infusions in patients receiving PN,
furthering the need for more evidence regarding treatment
of hyperglycemia in PN patients.
Currently, as recommended by ACE/ADA, insulin is the
most appropriate agent for management of hyperglycemia
[25]. There are many methods by which insulin can be
administered to patients receiving PN, including subcuta-
neous administration, insulin infusion, addition of insulin
to the PN bag, or a combination of these methods. No head
to head comparisons of these methods are available at this
time to comment on the best available technique. Previously,
there was a controversy surrounding the amount of insulin
available when mixed with PN solutions. However, Dunham
et al. [26] published a very well-designed study showing the
recovery of regular insulin from all-in-one PN mixtures in
ethylene vinyl acetate bags to be up to 95%. Surprisingly,
there have been very few studies describing glucose control
in PN patients with hyperglycemia treated with insulin
provided in the PN mixture. There is some discordant
opinion among PN experts regarding insulin delivery via
this method, and therefore no consistent comment can be
provided regarding the safety and eﬀect of this method of
intervention.
Glucose management strategies in the critically ill PN
recipient should involve frequent glucose monitoring and
implementation of IV insulin infusion. The 2009 ACE/ADA
recommends IV insulin infusions for all critically ill patients.
Thetargetbloodglucoseisrecommendedtobekeptbetween
7.8 to 10mmol/L. Administration of insulin infusions to PN
patients with hyperglycemia in the noncritically-ill setting
would be a signiﬁcant burden on the system, given the
extra monitoring required and nursing care involved. In the
ICU setting, one-on-one nursing allows the adoption of a
tighter glycemic control/insulin protocols; however, this is
not practical for ward patients.
GlucosemanagementstrategiesinthenoncriticallyillPN
recipient typically involve subcutaneous insulin in a variety
of breakdowns. The ACE/ADA recommends basal/bolus/
correction subcutaneous insulin regiments tailored to the
individual patient with adequate adjustments as the patient
condition changes, Targeting random blood glucose levels
of less than 10mmol/L, and once the patient is eating
premeal blood glucose targets of less than 7.8mmol/L. A
multidisciplinary approach may be necessary for successful
implementation of eﬀective glycemic management in the
hospital setting. Individualized plans taking into account the
patient proﬁle, nursing support, and monitoring capabilities
are likely the most prudent way to proceed until further
studies are done regarding optimal therapy regimens. Most
noncritically ill patients can be managed eﬀectively using
subcutaneous route of delivery. However, sliding scale regi-
mens, deﬁned as administration of a preestablished amount
ofrapidactinginsulininresponsetohyperglycemia,areinef-
fective [23, 27]. This method does not emulate the natural
circadian rhythm; it is more reactive than proactive and does
not include basal insulin. The ACE/ADA discourages use of
these sliding scales due to wide ﬂuctuations in glucose levels
documented in several observational studies. A prospective
randomized in 130 hospitalized noncritically ill patients with
type 2 diabetes showed that basal-bolus insulin regiment
(using a daily long-acting insulin analog with preprandial
rapid-acting insulin analog) was superior to a standard
sliding scale protocol. The target blood glucose of less than
7.8mmol/L was achieved in 66% of patients in the basal-
bolus group versus only 38% of patient in the sliding scale
group [28].
Management of hyperglycemia and insulin dosing in
patients receiving parenteral nutrition should be done on
an individual basis, regardless of indication. Insulin dosing
requirements may change rapidly as the patient’s underlying
illness evolves. It is recommended that insulin requirements
be reassessed after any changes in nutritional status, and
certainly with changes in the nutrition support prescription
and with changes in oral intake. Close glucose monitoring
with frequent insulin dose adjustments is a critical part of
eﬀective glycemic management, and a generalized cookbook
approach may not be suitable for patients on PN. The
A.S.P.E.N guidelines recommend q6 hour capillary blood
sugars. All four studies had less than optimal glucose
monitoring in their hyperglycemic patients and only one
looked at outcomes associated with monitoring. Sarkisian
et al. [12] did not show an increased mortality associated
with frequency of glucose monitoring. However, this was
a retrospective study including only 100 patients in a
noncritically ill setting
We can only infer a trend towards increased mortality
and morbidity in hyperglycemic PN patients from these
studies because they were limited in their design; all were
retrospective and diﬀered in glycemic targets. Their patient6 Gastroenterology Research and Practice
populations were not identical and their protocols for
monitoring blood sugars varied. It is diﬃcult to conclude
from these studies that hyperglycemia alone led to the
observed complications and increased mortality, as preexist-
ing comorbid conditions and indications for PN were not
accounted for. Additionally, as we could not separate the
critically ill from the noncritically ill in these studies, the
increased mortality seen in patients with poorly controlled
glucose may have been a result of preexisting conditions
and a sicker population. Our review has inherent limitations
since our search yielded only four papers which varied in
their design not allowing us to statistically combine the
results or draw sound conclusions.
5. Conclusion
Hyperglycemia is associated with poor outcomes in patients
receiving PN; this applies to patients with and without
diabetes and both critically ill and noncritically ill. There is a
signiﬁcant increase in mortality when blood sugars are above
10mmol/L. There is a suggestion of increased complication
rates in this patient population but further studies need to
be done to conﬁrm these ﬁndings. These studies suggest
that the most acceptable level of blood glucose should range
between 6.3–9.1mmol/L. Conclusions regarding the most
appropriatemethodformanagementofhyperglycemiacould
not be drawn from this cohort due to lack of information
regarding therapy. Given the lack of standardized protocols
regarding monitoring and therapy in this population, a large
prospective,randomizedcontrolledtrialinpatientsreceiving
PN with hyperglycemia is necessary to determine optimal
monitoring, optimal delivery of insulin, and whether the
control of blood glucose can improve outcomes in this
patient population.
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